2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Computer Vision, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5671 A Phase 2 study of zanubrutinib and venetoclax (ZV) in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)

Inhye E Ahn, MD, Svitlana Tyekucheva, PhD2, Jennifer L. Crombie, MD3, Austin I Kim, MD4, David C Fisher, MD5, Nancy E Kaddis6, Jon E Arnason, MD7, John P Winters, III, MD8, Hang Phan9, Megan Cravinho10, Aaron Zou11, Victoria Patterson, BSN, RN12, Stacey M. Fernandes, BS13, Matthew S Davids, MD, MMSc14, Jennifer R. Brown, MD, PhD15
1 Dana-Farber Cancer Institute, Boston, United States
2 Dana-Farber Cancer Institute, Boston, United States
3 Dana-Farber Cancer Institute, Boston, United States
4 Dana-Farber Cancer Institute, Boston, United States
5 Dana-Farber Cancer Institute, Boston, United States
6 Dana-Farber Cancer Institute at South Shore Health, Weymouth, United States
7 Beth Israel Deaconess Medical Center, Boston, United States
8 New England Cancer Specialists, Scarborough, United States
9 Dana-Farber Cancer Institute, Boston, United States
10 Dana-Farber Cancer Institute, Boston, United States
11 Dana-Farber Cancer Institute, Boston, United States
12 Dana-Farber Cancer Institute, Boston, United States
13 Dana-Farber Cancer Institute, Boston, United States
14 Dana-Farber Cancer Institute, Boston, United States
15 Dana-Farber Cancer Institute, Boston, United States

Background

The doublet combination of a Bruton tyrosine kinase inhibitor (BTKi) and B-cell lymphoma 2 inhibitor (BCL2i) is an effective initial therapy in CLL. Data are limited for the efficacy and safety of a doublet BTKi/BCL2i regimen in R/R CLL.

Methods

In this investigator-sponsored, multicenter trial, patients (pts) with R/R CLL were enrolled into non-randomized cohorts defined by prior exposure to targeted therapy (NCT05168930). Eligible pts for the main cohorts were either naïve to (Cohort A) or exposed to BTKi and/or BCL2i but without progression on targeted therapy (Cohort B). Study therapy was fixed-duration ZV for 15 cycles in 28-day cycles. Zanubrutinib 160 mg BID was started on Cycle (C) 1 Day (D) 1, followed by the initiation of venetoclax on C4D1 using the standard 5-week ramp-up. Retreatment with 12Cs of ZV was initiated if progressive disease (PD) meeting iwCLL treatment indications occurred after having detectable minimal residual disease (MRD) at the end of the initial treatment with ZV (EOT), or if MRD recurrence occurred after achieving undetectable MRD (uMRD4) at EOT. The primary endpoint was the rate of uMRD4 in bone marrow (BM). MRD was assessed in BM and peripheral blood (PB) using multi-color flow cytometry with a 10-4 cutoff. 90-gene targeted NGS was applied to pretreatment samples. Adverse events (AEs) and clinical response were assessed by CTCAE v5 and iwCLL guidelines, respectively.

Results

The study completed accrual of 40 pts in the main cohorts. The median age at enrollment was 68 years. 70% were male, 65% had unmutated IGHV (U-IGHV), and 28% had TP53 aberration. None had BTK/PLCG2 mutations at baseline. BCL2 mutation was not assessed. The median number of prior lines of therapy was 1 for Cohort A (targeted therapy-naïve) and 2 for Cohort B (targeted therapy-exposed). Most (85%) pts in Cohort A received chemoimmunotherapy (CIT). All pts in Cohort B were single-exposed to either a BTKi (65%) or a BCL2i (35%). A third (35%) of Cohort B also received prior CIT.

As of July 2026, the median follow-up was 25 months. Of 40 pts enrolled, 2 (5%) went off study before reaching EOT (atrial fibrillation [Afib] and bladder cancer in one pt each). Most pts completed the planned 15 cycles (88%) or were on the last 5 cycles of ZV (8%). Using an intent-to-treat analysis including pts who went off study and excluding those who had not yet reached EOT, the overall response rate at EOT was 85% for Cohort A (n=20 evaluable, 25% in complete response [CR]) and 87% for Cohort B (n=15 evaluable, 33% in CR). The rate of BM uMRD4 at EOT was 25% for Cohort A and 20% for Cohort B. There were 7 pts with PD and no deaths on study. The 2-year PFS rate was 92% (95% confidence interval [CI] 82-100%). 

After EOT, 4 pts went off study (n=2 PD, n=2 withdrawal of consent). Of 7 pts who progressed, 4 began retreatment with ZV (2 pts each from Cohorts A and B). All 4 pts on retreatment had detectable MRD at EOT and developed symptomatic PD at retreatment. Baseline prognostic markers of pts on retreatment were notable for U-IGHV (all 4 pts), TP53 mutation (n=1), and KRAS mutations (n=2). Median time from EOT to retreatment was 11 months. One pt progressed 9 months after completing retreatment. Three pts were on ongoing retreatment at the time of data analysis.

The most common treatment-emergent AE was bruising (73%, all Grade [G] 1), followed by infection (63%, including 18% with G3 and none with G4+). COVID-19 infection occurred in 5 pts (13%, all G1-2). The most common hematologic AE was neutropenia (50%, 38% G3-4). Febrile neutropenia and sepsis were uncommon (3% each). Three (8%) pts developed Afib; only one pt with G3 Afib went off study during C1. Hypertension occurred in 23% (10% G3); none led to treatment discontinuation. There was no tumor lysis syndrome.

Conclusions

Fixed-duration combination therapy with ZV was active and well-tolerated in R/R CLL, including in pts with or without prior exposure to targeted agents. The 2-year PFS rate was 92% (95% CI 82-100%). MRD kinetics data will be presented at the meeting.

Inhye E Ahn, MD: AbbVie - Honoraria; Research To Practice - Honoraria; BeOne - Research Funding; Genentech - Research Funding; Lilly - Research Funding; Lilly - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony)